BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33745434)

  • 1. Mannosylated Solid Lipid Nanocarriers of Chrysin to Target Gastric Cancer: Optimization and Cell Line Study.
    Pandey SS; Shaikh FI; Gupta AR; Vaidya RJ
    Curr Drug Deliv; 2021; 18(10):1574-1584. PubMed ID: 33745434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
    Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
    J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation of Chrysin-Phospholipid complex loaded solid lipid nanoparticles - storage stability and in vitro anti-cancer activity.
    Komath S; Garg A; Wahajuddin M
    J Microencapsul; 2018 Sep; 35(6):600-617. PubMed ID: 30557060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.
    Vieira AC; Chaves LL; Pinheiro M; Ferreira D; Sarmento B; Reis S
    Int J Nanomedicine; 2016; 11():2601-17. PubMed ID: 27354792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
    Das S; Ng WK; Tan RB
    Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization,
    Patel MH; Mundada VP; Sawant KK
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1242-1257. PubMed ID: 30880488
    [No Abstract]   [Full Text] [Related]  

  • 7. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
    Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
    Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines.
    Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Alsaidan YSM; Alfaiz SA; Haque A; Az A; Alhazzani K
    Chem Phys Lipids; 2020 Nov; 233():105003. PubMed ID: 33096096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Dapagliflozin Solid Lipid Nanoparticles as a Novel Carrier for Oral Delivery: Statistical Design, Optimization, In-Vitro and In-Vivo Characterization, and Evaluation.
    Unnisa A; Chettupalli AK; Al Hagbani T; Khalid M; Jandrajupalli SB; Chandolu S; Hussain T
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
    Chokshi NV; Khatri HN; Patel MM
    Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles.
    Alsulays BB; Anwer MK; Soliman GA; Alshehri SM; Khafagy ES
    Int J Nanomedicine; 2019; 14():9127-9138. PubMed ID: 31819423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
    Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
    AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid lipid nanoparticles for the controlled delivery of poorly water soluble non-steroidal anti-inflammatory drugs.
    Kumar R; Singh A; Garg N; Siril PF
    Ultrason Sonochem; 2018 Jan; 40(Pt A):686-696. PubMed ID: 28946474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway.
    Wang J; Zhu R; Sun X; Zhu Y; Liu H; Wang SL
    Int J Nanomedicine; 2014; 9():3987-98. PubMed ID: 25187702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel.
    Sahu PK; Mishra DK; Jain N; Rajoriya V; Jain AK
    Drug Dev Ind Pharm; 2015 Apr; 41(4):640-9. PubMed ID: 24564799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line.
    Bhatt H; Rompicharla SVK; Komanduri N; Aashma S; Paradkar S; Ghosh B; Biswas S
    Curr Drug Deliv; 2018; 15(9):1271-1283. PubMed ID: 29732970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Perphenazine-Loaded Solid Lipid Nanoparticles: Statistical Optimization and Cytotoxicity Studies.
    Farsani PA; Mahjub R; Mohammadi M; Oliaei SS; Mahboobian MM
    Biomed Res Int; 2021; 2021():6619195. PubMed ID: 33997026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silibinin loaded inhalable solid lipid nanoparticles for lung targeting.
    Patel P; Raval M; Airao V; Bhatt V; Shah P
    J Microencapsul; 2022 Jan; 39(1):1-24. PubMed ID: 34825627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation, Characterization, and Evaluation of Eudragit-Coated Saxagliptin Nanoparticles Using 3 Factorial Design Modules.
    Alhamhoom Y; Ravi G; Osmani RAM; Hani U; Prakash GM
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364338
    [No Abstract]   [Full Text] [Related]  

  • 20. Design, characterization and in vivo performance of solid lipid nanoparticles (SLNs)-loaded mucoadhesive buccal tablets for efficient delivery of Lornoxicam in experimental inflammation.
    Zewail MB; F Asaad G; Swellam SM; Abd-Allah SM; K Hosny S; Sallah SK; E Eissa J; S Mohamed S; El-Dakroury WA
    Int J Pharm; 2022 Aug; 624():122006. PubMed ID: 35820515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.